See other companies on Welcome to the Jungle
Nostos Genomics
AI-driven genetic analysis platform
- 21-100 employees
- Healthcare
- B2B
- Artificial Intelligence
- Charlottenburg, Berlin, Germany
Jump to section
Company mission
To help people with genetic diseases to start a new journey.
Our take
About 475 million people, or 10 percent of the world's population, suffer from rare diseases, and over 80% of them are genetic in nature. Nostos Genomics is an AI-driven genetic analysis platform that enables genetic testing labs to give more people a clear and fast diagnosis.
The platform’s AI solution “AION” automatically identifies pathogenic variants and genetic mutations through leveraging a combination of machine learning and functional genomics. Typically, the average diagnosis time for these tests is 4-5 years, but sometimes patients can be looking at closer to a decade. This lead time paired with extensive and expensive workups and testing is telling of how transformative Nostos Genomics technology can be.
The company recently received a new influx of funding which it hopes to put towards quickly expanding the team, entering a series of new markets including the US, and conducting more studies to further develop its platform.
Kirsty
Company Specialist at Welcome to the Jungle
Benefits
- Develop your personal skills and knowledge with resources like books and courses to learn continuously.
- Dynamic and flexible work environment that you can design (incl. remote work options).
- Participate in our success with equity options.
- Possibility to grow with the company and influence our direction.
- Regular social activities: participate only if you feel like it.
- Car allowance + flexible travel reimbursement.
Company values
- Transparency
- Kindness
- Ownership
- Personal growth
Funding (1 round)
Feb 2022
$5.2m
SEED
Total funding: $5.2m
This company has top investors
Leadership
David Gorgan
(CEO)Started their career as a Medic in the Swiss Armed Forces went onto Found and Direct START Hack for START Global. Also worked in Business Development for Merantix and a Research Assistant for Centre for Digital Health Interventions.
Rocío Acuña Hidalgo
(CTO)12+ years of research experience in genetic disease and expertise in state-of-the-art genomic and sequencing technologies. Most recently working as a Postdoctoral Researcher for Max Planck Institute for Molecular Genetics and becoming a Member of the Medical and Scientific Advisory Board for both SETBP1 Society and The Schinzel-Giedion Syndrome Foundation.